

A SAM analogue-utilizing ribozyme for site-specific RNA alkylation in living cells

Received: 26 August 2022

Accepted: 8 August 2023

Published online: 04 September 2023

 Check for updatesTakumi Okuda¹, Ann-Kathrin Lenz¹, Florian Seitz¹, Jörg Vogel^{2,3} & Claudia Höbartner^{1,4}✉

Post-transcriptional RNA modification methods are in high demand for site-specific RNA labelling and analysis of RNA functions. In vitro-selected ribozymes are attractive tools for RNA research and have the potential to overcome some of the limitations of chemoenzymatic approaches with repurposed methyltransferases. Here we report an alkyltransferase ribozyme that uses a synthetic, stabilized *S*-adenosylmethionine (SAM) analogue and catalyses the transfer of a propargyl group to a specific adenosine in the target RNA. Almost quantitative conversion was achieved within 1 h under a wide range of reaction conditions in vitro, including physiological magnesium ion concentrations. A genetically encoded version of the SAM analogue-utilizing ribozyme (SAMURI) was expressed in HEK293T cells, and intracellular propargylation of the target adenosine was confirmed by specific fluorescent labelling. SAMURI is a general tool for the site-specific installation of the smallest tag for azide-alkyne click chemistry, which can be further functionalized with fluorophores, affinity tags or other functional probes.

Site-specific chemical modification methods that enable precise post-synthetic or post-transcriptional functionalization of RNA provide robust means to probe and manipulate RNA functions in vitro and in cells^{1,2}. Chemoenzymatic strategies with repurposed methyltransferase (MTase) protein enzymes and *S*-adenosylmethionine (SAM or AdoMet) derivatives have emerged as powerful methods for targeted RNA modification^{3–6}. Several types of chemically modified SAM analogue have been developed, including variants for the transfer of alkyne^{7,8} or azide tags^{9,10}, photoreactive groups¹¹, fluorophores¹² or biotin¹³. The installation of bioorthogonal functional groups allows further derivatization via click reactions for several purposes, including affinity purification⁸, chemical degradation¹⁴ or fluorescent labelling¹⁵ of target RNAs. In some examples, modified SAM analogues have been applied for target modification in the intracellular context by using a cascade reaction of methionine adenosyl-transferase (MAT) and MTases^{16–18}. Such metabolic approaches are designed to give global modifications of DNA, RNA or proteins^{16,19}, but often lack target specificity, because

many cellular MTases maintain a common SAM recognition domain. To address specific RNA targets beyond the mRNA cap²⁰, either structure-specific tRNA MTases²¹, or C/D box snoRNPs with sequence-specific guide RNAs⁷, have been used in vitro.

Ribozymes have gained increasing momentum as an alternative sequence-specific approach for post-synthetic RNA modification^{2,22}. Usually, the catalytic core is flanked by binding arms that hybridize to a particular target sequence by Watson–Crick base-pairing, placing the target nucleotide into the active site for reaction with a specific, non-covalently bound cofactor. Thus, these *trans*-active ribozymes combine both functions—the guide and the catalyst—in one RNA molecule that interacts with the RNA target. Several combinations of ribozymes and cofactors for RNA labelling have been identified by in vitro selection. For example, ribozymes catalyse the attachment of fluorescently labelled nucleotides^{23,24} or acyclic nucleotide analogues²⁵ to a specific internal 2'-OH group of the target RNA, or at the 3'-end²⁶. Other classes of ribozymes work in *cis*, that is, they catalyse

¹Institute of Organic Chemistry, Julius-Maximilians-Universität Würzburg, Würzburg, Germany. ²Institute of Molecular Infection Biology (IMIB), Julius-Maximilians-Universität Würzburg, Würzburg, Germany. ³Helmholtz Institute for RNA-based Infection Research (HIRI), Helmholtz Centre for Infection Research (HZI), Würzburg, Germany. ⁴Center for Nanosystems Chemistry (CNC), Julius-Maximilians-Universität Würzburg, Würzburg, Germany. ✉e-mail: claudia.hoebartner@uni-wuerzburg.de

their own modification, for example, via self-alkylation with electrophilic iodoacetyl groups^{27,28} or reactive epoxide probes^{29,30}. The most recent addition to the repertoire of RNA-catalysed reactions concerns site-specific RNA methylation. The *in vitro*-selected methyltransferase ribozyme MTR1 uses *O*⁶-methylguanine (m⁶G) as cofactor^{31,32}, and a split riboswitch uses an engineered ligand *O*⁶-methyl pre-queuosine (m⁶preQ₁)³³ to methylate their RNA targets at the Watson–Crick base-pairing face to produce m¹A (ref. 31) and m³C (ref. 33), respectively. Self-methylation at the Hoogsteen edge to install m⁷G was achieved by an *in vitro*-selected copper ion-dependent ribozyme that uses native SAM as cofactor³⁴. In analogy to chemoenzymatic MTase engineering, these recently reported methyltransferase ribozymes have high potential to be repurposed for RNA labelling. However, only MTR1 has so far been addressed to a variety of RNA target sequences, including tRNAs, and m⁶preQ₁- and SAM-dependent ribozymes suffer from a severely restricted sequence scope.

In this Article we report a ribozyme that catalyses the sequence-specific transfer of a propargyl group from bioorthogonal SAM analogues to the minor groove side of a specific adenine in various RNA target sequences. We explore the scope of the bioorthogonal SAM analogue-utilizing ribozyme and find that the catalytic activity is retained even at low Mg²⁺ concentrations. This feature enables the intracellular site-specific RNA modification upon expression of the ribozyme in living human cells.

Results and discussion

Cofactor design and synthesis

Synthetic derivatives of the natural cofactor SAM (Fig. 1a) carrying allyl, propargyl and further extended groups at the sulfonium centre have been shown to be accepted by various types of MTase for alkylating DNA, RNA, proteins and small molecules^{35,36}. Double-activated cofactor analogues contain an unsaturated bond at the β carbon to stabilize the transition state by hyperconjugation and to rescue the reduced reaction rates compared to the transfer of a methyl group³⁷. To further increase the reactivity for the nucleophilic attack, the sulfur centre was replaced by selenium, and propargylated adenosyl selenomethionine (ProSeAM, also known as SeAdoYn) has become a heavily investigated cofactor for MTase protein enzymes^{38,39}. A similar approach using artificial SAM analogues would be attractive for alkyltransferase ribozymes, but the rather poor chemical stability of ProSeAM and its analogues limits their utility as reagents for *in vitro* selection of catalytic RNA. Several pathways contribute to the spontaneous decomposition in aqueous environment⁴⁰. Propargylated SAM undergoes rapid hydration of the triple bond at physiological pH, probably via an allene intermediate, and the major decomposition pathway for ProSeAM at physiological pH involves an intramolecular nucleophilic attack of the carboxylate group, resulting in breaking the weak selenium–carbon bond¹⁹. This intramolecular lactonization of the 2-aminobutyrate moiety affords the by-products homoserine lactone and *Se*-propargyl-5'-selenoadenosine (Fig. 1b). To avoid this side reaction, we designed a more stable and bioorthogonal propargylic SAM analogue, which we termed ProSeDMA (for propargylic *Se*-2,6-diaminopurinribosyl-selenomethionineamide) (Fig. 1c). The nucleophilic carboxylate was replaced by an amide group to prevent the intramolecular S_N2 reaction. In addition, 2-aminoadenosine (also known as 2,6-diaminopurine riboside, rDAP) was used as the nucleoside, with the aim to increase the binding affinity between cofactor and ribozyme by introducing an extra hydrogen-bond donor. The chemical synthesis of ProSeDMA involved four steps, starting from the protected α-aminoamide alcohol **1**, via transformation to the selenohomocystine amide **3** (Fig. 1d). After reduction of the diselenide, reaction with 5'-chloro-rDAP afforded the selenoether **4**. The propargyl group was installed by alkylation in the presence of a Lewis acid, and ProSeDMA (**5**) was purified by reversed-phase (RP) HPLC. Analogous cofactors with *Se*-methyl (MeSeDMA, **6**) and *Se*-allyl groups (AllySeDMA, **7**) were also

prepared, as well as the *N,N*-dimethylamide **8**, in which the amide group of ProSeDMA was further blocked by alkylation (Fig. 1e). In addition, we prepared an analogous α-hydroxy-amide cofactor **9**, which we considered an alternative *in vitro*-selection substrate. Each of these cofactors was obtained as a mixture of four diastereomers, which were not separated.

The chemical stability of ProSeDMA was compared to ProSeAM (Fig. 1f) under three different pH conditions (pH 6, 7 and 8). ProSeAM was rapidly degraded even at pH 6, and almost all of it was converted to *Se*-propargyl-5'-selenoadenosine after 1 h. In contrast, ProSeDMA was much more stable, with less than 5% loss after 1 h, and still more than 60% of the intact material remaining after 5 h of incubation at pH 7.0.

Next, we investigated the bioorthogonality of ProSeDMA, expecting that the terminal amide substitution and 2-aminoadenosine modification probably prevent recognition by native MTases. We chose the bacterial MTase M.EcoRI and plasmid DNA for enzymatic modification, as previously described³⁷. The modification efficiency was evaluated by enzymatic digestion with the restriction enzyme R. EcoRI after MTase treatment (Extended Data Fig. 1). If the cofactor is accepted and the target site is modified by MTase, digestion by the restriction enzyme will be suppressed. Analogous reactions with SAM, ProSeAM, ProSeDMA (**5**) and MeSeDMA (**6**) were performed in parallel. The digestion pattern of the ProSeDMA-containing sample was almost the same as in the experiment without cofactor. This result suggests that ProSeDMA was not recognized as a cofactor by EcoRI MTase. By contrast, ProSeAM, and surprisingly also MeSeDMA, showed similar activity to SAM. Thus, the combination of propargyl and amide modification provided sufficient structural change to escape from MTase recognition, and ProSeDMA is a potential candidate to serve as a bioorthogonal cofactor for intracellular propargyl modification of RNA with a suitable ribozyme.

In vitro selection of ProSeDMA utilizing ribozyme

Alkyltransferase ribozymes for use with ProSeDMA were identified by *in vitro* selection from a structured RNA library that contained a random region of 40 nucleotides between a pair of recognition arms complementary to the RNA substrate region, leaving a single adenosine unpaired in the middle of the target RNA sequence (Fig. 2a and Extended Data Fig. 2)^{23,31}. Two independent selection experiments were performed using ProSeDMA (**5**) and its α-hydroxy analogue **9** as co-substrates. After RNA folding and incubation with the cofactor at pH 7.5 and 37 °C for 1 h, the transferred propargyl group was reacted with biotin azide under Cu-catalysed azide-alkyne cycloaddition (CuAAC) reaction conditions. The biotinylated RNA molecules were then separated via streptavidin affinity purification on magnetic beads. The captured RNAs were amplified by reverse transcription and polymerase chain reaction (PCR). The generated dsDNA template was transcribed by T7 RNA polymerase, and the enriched RNA library was used in the next round of selection. After eight rounds, the enriched library was cloned and sequenced, and individual ribozyme candidates were screened for activity by a streptavidin gel shift assay (Extended Data Fig. 3) with both cofactors **5** and **9**. Interestingly, the ribozyme candidates from the selection with cofactor **5** only recognized their cognate α-amino cofactor ProSeDMA, while candidate ribozymes from the selection with cofactor **9** showed promiscuous activity with both **5** and **9**. The RNA sequence **Rz3** showed the highest reactivity of all screened ribozyme candidates, and was chosen for further characterization and optimization. The **Rz3** ribozyme retained its catalytic activity in an intermolecular set-up (*in trans*). Strategic mutations in the binding arms that fixed mismatched base pairs or bulged out nucleotides indicated the localization of the reacting adenosine (A5), which was further confirmed by primer extension assays and by re-targeting ('transplanting') the ribozyme to a different adenosine (A9) in the RNA sequence (Extended Data Fig. 4). Full activity was maintained when the base pairs flanking the modification site were exchanged, but mismatches were not tolerated (Extended Data Fig. 4d). The predicted stem loop in the ribozyme core was stabilized by a UUCG tetraloop.




Fig. 1 | Design and characterization of ProSeDMA. a, Chemical structure of SAM. **b**, Major degradation pathway of ProSeAM. **c**, Concept of ProSeDMA. Terminal amide substitution inhibits self-degradation, and 2-aminoadenosine may assist binding to a ribozyme. DAP = 2,6-diaminopurine. **d**, Synthesis of ProSeDMA. The asterisk indicates a stereocentre. **e**, Other SeDMA analogues

synthesized. **f**, Stability comparison between ProSeDMA (left) and ProSeAM (right). 1 mM cofactor was incubated in 50 mM HEPES (pH 7.0), 120 mM KCl, 5 mM NaCl and 10 mM MgCl₂ at 37 °C. Aliquots were analysed by RP-HPLC, monitored at 260 nm.

The engineered ribozyme containing a 17-nt catalytic core was named SAMURI (for SAM analogue-utilizing ribozyme) (Fig. 2b).

Characterization of SAMURI-catalysed RNA alkylation

For detailed characterization, SAMURI was hybridized to the target RNA with two 8-nt binding arms and showed over 90% *trans*-propargylation efficiency after 1-h incubation at 37 °C with 10 μM ProSeDMA. The

modified RNA was separable from the unmodified RNA substrate by anion-exchange HPLC and denaturing PAGE (Fig. 2c). The reacted adenosine was localized at A9, as confirmed by the shifted band pattern in alkaline hydrolysis and RNase T1 digestion assays (Fig. 2d). The precise modification site on A9 was then examined by atomic mutagenesis. Adenosine has several possible nucleophilic positions (N1, N3, N6, N7 and the 2'-OH group), which were individually addressed by the

respective deaza or deoxy nucleosides (Fig. 2e). The substrate RNAs with 1-deazaadenosine (c^1A) or 7-deazaadenosine (c^7A) showed similar reactivity to unmodified adenosine. The RNA with 2'-deoxyadenosine (dA) showed two products of lower intensity (31% and 24%). By contrast, the RNA containing 3-deazaadenosine (c^3A) did not give any modified product. These results strongly suggest that the N3 nitrogen is essential for catalytic activity, whereas N1 and N7 are dispensable.

Alkylation of adenosine at N3 in DNA is known to cause depurination⁴¹, and the second product observed with the dA-containing substrate is consistent with the formation of an abasic site. This mechanism is exploited by DNA targeting natural products and minor groove-binding cytotoxic agents⁴². In contrast, N3 alkylation of adenosine in RNA has barely been investigated, despite its biological importance⁴³ and the mechanistic involvement of adenine-N3 in natural ribozymes⁴⁴. Thus, to further characterize the product produced by SAMURI, the modified RNA was analysed by MS (Fig. 2f). The addition of a propargyl group to the target RNA (+38 Da) was detected by matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass analysis when the modified RNA was directly measured after the reaction. Surprisingly, after purification by denaturing PAGE, the mass spectrum of the modified RNA showed a loss of 10 Da. This RNA could still undergo CuAAC with biotin azide, confirming that the propargyl group was still intact (Fig. 2c). Interestingly, the propargylated RNAs containing c^1A and c^7A showed the expected mass of +38 Da, but not the +28 Da product that was observed for the parent adenosine (Extended Data Fig. 5). Instead, the electrospray ionization (ESI)-MS trace of the alkylated c^1A sample showed a depurinated fragment, which was not seen for the c^7A sample. Combining the results of atomic mutagenesis and mass analysis, a plausible modification process for adenosine is presented in Fig. 2g. SAMURI-catalysed alkylation of the N3 nitrogen enhances the electrophilicity of C2 for the attack of water, which results in ring opening followed by deformylation to produce a stable propargylated aminoimidazole nucleoside as product. The absence of the N1 nitrogen in c^1A prevents ring opening, but results in a weaker glycosidic bond, while the missing N7 nitrogen in c^7A prevents depurination.

To further confirm these mechanistic hypotheses, the PAGE-purified propargylated RNA was digested with snake venom phosphodiesterase (SVPD) and alkaline phosphatase enzymes, and the mononucleoside mixture was analysed by liquid chromatography-mass spectrometry (LC-MS; Fig. 2h). Interestingly, no new peak was detected in the UV chromatogram at 260 nm in addition to the standard four nucleosides, but the intensity of the adenosine peak was decreased. This result suggested that, upon reaction, the absorption of adenosine at 260 nm was reduced or lost, which is consistent with the proposed imidazole riboside depicted in Fig. 2g. Indeed, the extracted ion chromatogram (EIC) detected nucleoside **12** at 14 min (m/z 296.13), which was overlapped with the guanosine peak. The masses of the direct N3-alkylation product **10** (m/z 306.12) and the formyl intermediate **11** were not found after the digestion. For reference, we also recorded LC-MS spectra of stable isomers of 3-propargyladenosine **10**, namely 1-propargyladenosine (p^1A), 2'-*O*-propargyladenosine ($p^{O2}A$) and N^6 -propargyladenosine (p^6A), which showed the expected EIC at m/z 306.12 at three different retention times. Based on the combined results

of atomic mutagenesis and MS, we conclude that SAMURI catalyses the transfer of the propargyl group from ProSeDMA to the N3 nitrogen of the unpaired adenosine A9 in the target RNA.

Kinetics and substrate scope of SAMURI

Next, we evaluated the specificity and reactivity of SAMURI under various reaction conditions. To rule out uncatalysed background reactions, we incubated substrate RNA with ProSeDMA at concentrations up to 100 μ M. In the absence of ribozyme, we did not observe any non-specific propargylation (Fig. 3a). Following the addition of SAMURI, the *trans*-propargylation was highly efficient, not only at the ProSeDMA concentration of 5 μ M, which was used during *in vitro* selection, but also at the fivefold lower concentration of 1 μ M (Fig. 3b), which still produced more than 60% product after 1 h incubation at 37 °C. With 10 μ M ProSeDMA and 10 mM Mg^{2+} , quantitative propargylation was achieved with an observed rate constant k_{obs} of 0.12 min^{-1} . Importantly, SAMURI retained its catalytic activity at physiological Mg^{2+} concentrations (Fig. 3c). The reaction rate was dependent on ProSeDMA concentration, with an apparent $K_{m,app}$ of 32 μ M at 0.5 mM Mg^{2+} , and 3.7-fold tighter binding at 10 mM Mg^{2+} ($K_{m,app} = 8.9 \mu$ M) (Fig. 3d,e).

To explore the interactions between the cofactor and ribozyme, we evaluated the reactivity of different SeDMA derivatives (Fig. 3f). We found that alkylation of the terminal amide was tolerated well. Dimethylamide **8** reacted almost as efficiently as the parent cofactor **5**, suggesting that the terminal amide is not strictly recognized within the catalytic core. In contrast, replacement of the α -amino group by an α -hydroxyl group (cofactor **9**) decreased the activity of the ribozyme, suggesting that the protonation state of the α -amino group is important for interaction. Together, these results suggested that the selenomethionine amino-acid side chain of ProSeAM may also be tolerated. Indeed, 60% propargylation was observed with 10 μ M ProSeAM within 1 h (Fig. 3f).

Next, we examined the scope of alkyl groups that can be transferred by SAMURI. Allyl derivative **7**, containing an *sp*² carbon in the β position to selenium, showed similar reactivity to ProSeDMA (Fig. 3f and Extended Data Fig. 6). On the other hand, the reaction with methyl derivative **6** was slowed down, indicating that the electrophilicity of the α carbon is dominant over the steric demand of the transferred alkyl group. At the standard concentration of 10 μ M MeSeDMA, ~20% methylated RNA product was formed after 24 h. The methylated and allylated RNAs were confirmed by MS of intact RNA, and by LC-MS after digestion of the products into mononucleosides. Interestingly, we found differences in the stability of the N3-alkylated adenosines. In both cases of methyl or allyl modification, intact N3-alkylated adenosine was observed in addition to the hydrated and deformylated products (Extended Data Fig. 7).

Although the methylation rate with MeSeDMA was ~600-fold slower than propargylation with ProSeDMA, the above results suggested that native SAM could also be a productive cofactor for SAMURI. Indeed, methylated RNA product was observed upon incubation of the target RNA with SAMURI and SAM; however, compared to MeSeDMA, a much higher concentration of 3 mM SAM was required to reach comparable methylation levels. Similarly, the 2,6-diaminopurine analogue


Fig. 2 | Identification and analysis of ProSeDMA utilizing ribozyme (SAMURI).

a, Schematic of SAMURI-catalysed *trans*-propargylation to target adenosine. **b**, Sequence and predicted secondary structure of SAMURI. **c**, Polyacrylamide gel electrophoresis (PAGE, top) and anion-exchange HPLC analysis (bottom) of the SAMURI-catalysed reaction of 17-mer substrate RNA (S, 5'-ACAUACUGAGCCUCAA-3') with and without ProSeDMA at 37 °C for 1 h; 1 μ M substrate RNA, 1 μ M SAMURI, 10 μ M ProSeDMA and 10 mM $MgCl_2$, pH 7.5. PAGE also shows the reactivity test of transferred alkyne by CuAAC with biotin azide (10 μ M mod. RNA, 500 μ M CuBr, 1 mM TBTA and 1 mM biotin azide in $H_2O/DMSO^t$ /BuOH = 5/3/1 at 37 °C for 1 h). AIE-HPLC = anion-exchange HPLC. **d**, Alkaline hydrolysis and RNase T1 digestion of reacted RNA (mod., product P) in comparison to untreated RNA

(unmod., S). The image is representative of two independent experiments with similar results. **e**, Atomic mutagenesis of substrate RNA. Reaction conditions are as in **c**. A representative gel image is shown, and a histogram showing individual data points and the mean \pm s.d. of three independent experiments. **f**, MALDI-TOF mass spectra of unmodified RNA (grey, $m/z = 6,155.04$), a mixture of modified RNA (blue, $m/z = 6,193.06$) and ribozyme, and modified RNA after PAGE purification (red, $m/z = 6,183.08$). **g**, Plausible reaction pathway causing a mass shift after purification. **h**, LC/MS analysis of the digested 12-mer substrate RNA (5'-CUACUGAGCCUU-3') before and after modification, showing the UV (260 nm) trace and extracted ion chromatogram (EIC, detecting $m/z = 296.13$). p^1A = 1-propargyladenosine, $p^{O2}A$ = 2'-*O*-propargyladenosine, p^6A = N^6 -propargyladenosine.

of SAM (called SDM) showed comparable RNA methylation levels when used at 3 mM (Fig. 3f and Extended Data Fig. 6). Consistent with the weak affinity, SAM was not able to compete with ProSeDMA in an inhibition assay. When the *trans*-propargylation reaction was performed with SAMURI and 10 μ M ProSeDMA in the presence of increasing SAM

concentration from 1 μ M up to 1 mM, the yield of alkylated RNA product remained constant at the high level above 80% in 1 h (Fig. 3g). From these results we conclude that SAM is not a competitive inhibitor of SAMURI, which is an important finding for intracellular applications. In addition, we note that SAMURI enables the site-specific installation






Fig. 3 | Characterization of SAMURI. **a**, Evaluation of unspecific modification by ProSeDMA. In the absence of ribozyme, 1 μM RNA substrate was incubated with an increasing concentration of ProSeDMA at 37 °C for 1 h. **b**, Catalytic activity of SAMURI under varying conditions. The ratio of RNA:SAMURI:ProSeDMA was kept at 1:10:10. Sub.RNA = substrate RNA. **c**, Mg^{2+} dependence of SAMURI (1 μM RNA, 1 μM SAMURI, 10 μM ProSeDMA, varying Mg^{2+} as indicated, 37 °C, 1 h). NR = no reaction. **d, e**, ProSeDMA concentration dependence of the observed rate constant k_{obs} at 10 mM Mg^{2+} (**d**) and 0.5 mM Mg^{2+} (**e**). Data are fitted to the Michaelis–Menten equation. **f**, Scope of SAMURI with various SAM analogues.

k_{obs} values were obtained under pseudo-first-order reaction conditions for 60 min. For MeSeDMA, SAM and SDM, incubation was extended to 24 h, and a linear fit was applied because of the low reactivity. All cofactors were used at 10 μM , except for SAM and SDM, which were used at 3 mM. **g**, Inhibition assay: SAMURI *trans*-propargylation activity was not inhibited by SAM. Conditions are as in **c**, with increasing concentrations of SAM as indicated. **a, b, c, f** show representative images of three independent experiments, with similar results. In **d, e, g**, individual data points and the mean \pm s.d. of three independent experiments are shown.

of m^3A in RNA, a modification that is challenging to synthesize chemically⁴⁵ and that has not yet been incorporated by solid-phase synthesis.

Intracellular activity of SAMURI

The findings that SAMURI was still active at low Mg^{2+} concentrations and was not inhibited by SAM encouraged the investigation of RNA-catalysed RNA propargylation in living cells. To explore this possibility, we designed plasmids for the expression of SAMURI in human cells. The *cis*-active SAMURI was placed in the F30 scaffold⁴⁶ together with the fluorogenic aptamer Broccoli⁴⁷ and the Tornado system for the production of circular RNA (cSAMURI, Fig. 4a), which has been shown to improve the stability of expressed functional RNAs in mammalian cells⁴⁸. The SAMURI-encoding plasmid was transfected in HEK293T cells and, after 48-h incubation, the expression of target ribozyme was visualized by staining the Broccoli aptamer with DFHBI-1T (Fig. 4b).

The cSAMURI-expressing cells were treated with increasing concentrations of ProSeDMA in growth medium (from 100 μM to 3 mM). Cell viability was not decreased under these conditions, suggesting that ProSeDMA is not strongly cytotoxic in this concentration range (Fig. 4c). We also estimated the cofactor uptake via LC-MS analysis of cleared cell lysate from untransfected cells (Extended Data Fig. 8). Using a calibration curve for the extracted ion count

of ProSeDMA in cell lysate (generated by known spiked concentrations), we found ~ 3 nmol ProSeDMA per 10^6 cells that were incubated in medium containing 1 mM ProSeDMA. These numbers are of the same order of magnitude as reported for bioorthogonal SAM analogues produced intracellularly from membrane-permeable amino acids and engineered SAM synthetases¹⁸. Therefore, ProSeDMA was sufficiently available for cSAMURI-expressing cells, from which total RNA was isolated and analysed. The intracellularly propargylated *cis*-active SAMURI was labelled with Cy5 azide, followed by visualization with in-gel fluorescence (Fig. 4d). The Cy5 channel image showed only one band, and its intensity increased with increasing concentrations of ProSeDMA in the medium. The same gel was stained by SYBR Gold to visualize total cellular RNA. The image shows the expected abundant cellular RNAs, such as transfer RNAs and ribosomal RNAs, and an additional band migrating approximately at the size of the 200-nt marker, which appeared only when the cells were transfected with the plasmid. This band stained with DFHBI-1T and represents the cyclized *cis*-active SAMURI-Broccoli-Tornado construct (cSAMURI). As expected, the ProSeDMA dose-dependent Cy5 signal (red) colocalized with the DFHBI-1T signal (green), indicated by the merged yellow colour in the multi-channel image of Cy5 and DFHBI-1T in Fig. 4d.




Fig. 4 | SAMURI activity in living cells. a, Schematic illustration of genetically encoded *cis*-active SAMURI. HEK293T cells grown in a cell culture dish were transfected with plasmid, and the cSAMURI-expressing cells were treated with ProSeDMA. The intracellularly propargylated RNA was isolated and labelled with Cy5 azide. The modification yield was quantified based on the fluorescence intensities of Cy5 and DFHBI-1T. **b**, Transfected cells stained with DFHBI-1T show expression of cSAMURI. **c**, Cell viability measured by trypan blue staining. Individual data points and the mean \pm s.d. of four independent experiments are

shown. **d**, Total RNA analysis on PAGE. The gel was visualized in the Cy5 channel, then stained with 20 μ M DFHBI-1T and then stained by SYBR Gold. **e**, Intracellular labelling efficiency of cSAMURI calculated from the Cy5/DFHBI-1T ratio, relative to the in vitro labelling efficiency of RNA extracted from cells that were not treated with ProSeDMA. The reference was prepared in the test tube using 200 ng total RNA, 50 μ M ProSeDMA and 10 mM $MgCl_2$, pH 7.5 at 37 $^{\circ}C$ for 1 h. Individual data points and the mean \pm s.d. of three independent experiments are shown. RNA mod. rel. = relative intracellular RNA modification efficiency.

For comparison of the labelling efficiency, total RNA was also extracted from transfected cells that produced cSAMURI but were grown in the absence of ProSeDMA. The isolated RNA was then treated with the cofactor in vitro, followed by click labelling with Cy5. Using the normalized Cy5/DFHBI-1T ratio, we estimate that ~17% of cSAMURI was propargylated in the cell (Fig. 4e). Comparison to an in vitro-transcribed RNA, which was enzymatically processed and circularized, showed that the cSAMURI extracted from HEK293T cells retained its activity in the presence of total RNA. Overall, these results are encouraging for the future development of SAMURI as a self-labelling tag for any RNA of interest and for engineering *trans*-active SAMURI variants to target endogenous RNAs, similar to approaches recently shown for F30-MTR1 targeting *Escherichia coli* transfer RNA³¹, and circular ADAR-recruiting guide RNAs (cadRNAs)⁴⁹ to target mRNAs.

Conclusions

In summary, we have reported SAMURI as an alkyltransferase ribozyme in combination with ProSeDMA as a bioorthogonal and stabilized SAM analogue. The replacement of the terminal carboxylic acid by an amide improved the chemical stability of ProSeDMA compared to previously reported propargylic SAM and SeAM derivatives. The catalytic activity of SAMURI was demonstrated in vitro and in living cells. The successful intracellular application was possible due to the low toxicity of ProSeDMA and the high activity of SAMURI under physiological Mg^{2+} concentrations. Using atomic mutagenesis and MS, we fully characterized the RNA-catalysed reaction of SAMURI and found that the modification occurred at N3 of an unpaired adenosine between the binding arms. Although N3-alkylated adenosines are usually prone to depurination, we found that the enhanced electrophilicity

at C2 provides a pathway for the favourable formation of a stable *N*-alkylated aminoimidazole nucleoside. Thus, SAMURI introduces the propargyl group site-specifically as a small clickable tag for RNA labelling. Moreover, SAMURI is permissive to ProSeDMA analogues, and can even use native SAM to synthesize m³A in RNA, which is a challenging chemical modification that cannot be prepared by solid-phase synthesis. This work expands the known repertoire of RNA-catalysed RNA modification reactions and suggests that appropriately designed cofactors and fine-tuned in vitro selection strategies are likely to create additional RNA-modifying ribozymes in the future. Desirable new ribozyme and cofactor combinations could then also enable strain-promoted click chemistry for applications in which the need for copper ions with the here-described propargyl groups is of any concern. Given the increasing importance of RNA technologies, we envision SAMURI to become a useful tool for RNA labelling and for studying the biology of damaged nucleobases in RNA.

Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41557-023-01320-z>.

References

1. Klöcker, N., Weissenboeck, F. P. & Rentmeister, A. Covalent labeling of nucleic acids. *Chem. Soc. Rev.* **49**, 8749–8773 (2020).
2. Depmeier, H., Hoffmann, E., Bornewasser, L. & Kath-Schorr, S. Strategies for covalent labeling of long RNAs. *ChemBioChem* **22**, 2826–2847 (2021).
3. Tomkuvienė, M., Mickute, M., Vilkaitis, G. & Klimasauskas, S. Repurposing enzymatic transferase reactions for targeted labeling and analysis of DNA and RNA. *Curr. Opin. Biotechnol.* **55**, 114–123 (2019).
4. Deen, J. et al. Methyltransferase-directed labeling of biomolecules and its applications. *Angew. Chem. Int. Ed.* **56**, 5182–5200 (2017).
5. Fischer, T. R. et al. Chemical biology and medicinal chemistry of RNA methyltransferases. *Nucleic Acids Res.* **50**, 4216–4245 (2022).
6. Muthmann, N., Hartstock, K. & Rentmeister, A. Chemo-enzymatic treatment of RNA to facilitate analyses. *Wiley Interdiscip. Rev. RNA* **11**, e1561 (2020).
7. Tomkuvienė, M. et al. Programmable sequence-specific click-labeling of RNA using archaeal box C/D RNP methyltransferases. *Nucleic Acids Res.* **40**, 6765–6773 (2012).
8. Hartstock, K. et al. Enzymatic or in vivo installation of propargyl groups in combination with click chemistry for the enrichment and detection of methyltransferase target sites in RNA. *Angew. Chem. Int. Ed.* **57**, 6342–6346 (2018).
9. Lukinavicius, G., Tomkuvienė, M., Masevicius, V. & Klimasauskas, S. Enhanced chemical stability of AdoMet analogues for improved methyltransferase-directed labeling of DNA. *ACS Chem. Biol.* **8**, 1134–1139 (2013).
10. Lauer, M. H. et al. Methyltransferase-directed covalent coupling of fluorophores to DNA. *Chem. Sci.* **8**, 3804–3811 (2017).
11. Anhäuser, L., Muttach, F. & Rentmeister, A. Reversible modification of DNA by methyltransferase-catalyzed transfer and light-triggered removal of photo-caging groups. *Chem. Commun.* **54**, 449–451 (2018).
12. Grunwald, A. et al. Bacteriophage strain typing by rapid single molecule analysis. *Nucleic Acids Res.* **43**, e117 (2015).
13. Osipenko, A. et al. Oligonucleotide-addressed covalent 3'-terminal derivatization of small RNA strands for enrichment and visualization. *Angew. Chem. Int. Ed.* **56**, 6507–6510 (2017).
14. Mikutis, S. et al. MeCLICK-Seq, a substrate-hijacking and RNA degradation strategy for the study of RNA methylation. *ACS Cent. Sci.* **6**, 2196–2208 (2020).
15. Schulz, D., Holstein, J. M. & Rentmeister, A. A chemo-enzymatic approach for site-specific modification of the RNA cap. *Angew. Chem. Int. Ed.* **52**, 7874–7878 (2013).
16. Shu, X. et al. A metabolic labeling method detects m⁶A transcriptome-wide at single base resolution. *Nat. Chem. Biol.* **16**, 887–895 (2020).
17. Michailidou, F. et al. Engineered SAM synthetases for enzymatic generation of AdoMet analogs with photocaging groups and reversible DNA modification in cascade reactions. *Angew. Chem. Int. Ed.* **60**, 480–485 (2021).
18. Wang, R. et al. Profiling genome-wide chromatin methylation with engineered posttranslation apparatus within living cells. *J. Am. Chem. Soc.* **135**, 1048–1056 (2013).
19. Bothwell, I. R. et al. Se-adenosyl-L-selenomethionine cofactor analogue as a reporter of protein methylation. *J. Am. Chem. Soc.* **134**, 14905–14912 (2012).
20. Bollu, A., Peters, A. & Rentmeister, A. Chemo-enzymatic modification of the 5' cap to study mRNA. *Acc. Chem. Res.* **55**, 1249–1261 (2022).
21. Motorin, Y. et al. Expanding the chemical scope of RNA: methyltransferases to site-specific alkylation of RNA for click labeling. *Nucleic Acids Res.* **39**, 1943–1952 (2011).
22. Micura, R. & Höbartner, C. Fundamental studies of functional nucleic acids: aptamers, riboswitches, ribozymes and DNAzymes. *Chem. Soc. Rev.* **49**, 7331–7353 (2020).
23. Ghaem Maghami, M., Scheitl, C. P. M. & Höbartner, C. Direct in vitro selection of *trans*-acting ribozymes for posttranscriptional, site-specific, and covalent fluorescent labeling of RNA. *J. Am. Chem. Soc.* **141**, 19546–19549 (2019).
24. Büttner, L., Javadi-Zarnaghi, F. & Höbartner, C. Site-specific labeling of RNA at internal ribose hydroxyl groups: terbium-assisted deoxyribozymes at work. *J. Am. Chem. Soc.* **136**, 8131–8137 (2014).
25. Ghaem Maghami, M., Dey, S., Lenz, A. K. & Höbartner, C. Repurposing antiviral drugs for orthogonal RNA-catalyzed labeling of RNA. *Angew. Chem. Int. Ed.* **59**, 9335–9339 (2020).
26. Samanta, B., Horning, D. P. & Joyce, G. F. 3'-end labeling of nucleic acids by a polymerase ribozyme. *Nucleic Acids Res.* **46**, e103 (2018).
27. Wilson, C. & Szostak, J. W. In vitro evolution of a self-alkylating ribozyme. *Nature* **374**, 777–782 (1995).
28. Sharma, A. K. et al. Fluorescent RNA labeling using self-alkylating ribozymes. *ACS Chem. Biol.* **9**, 1680–1684 (2014).
29. McDonald, R. I. et al. Electrophilic activity-based RNA probes reveal a self-alkylating RNA for RNA labeling. *Nat. Chem. Biol.* **10**, 1049–1054 (2014).
30. Krochmal, D. et al. Structural basis for substrate binding and catalysis by a self-alkylating ribozyme. *Nat. Chem. Biol.* **18**, 376–384 (2022).
31. Scheitl, C. P. M., Ghaem Maghami, M., Lenz, A. K. & Höbartner, C. Site-specific RNA methylation by a methyltransferase ribozyme. *Nature* **587**, 663–667 (2020).
32. Scheitl, C. P. M., Mieczkowski, M., Schindelin, H. & Höbartner, C. Structure and mechanism of the methyltransferase ribozyme MTR1. *Nat. Chem. Biol.* **18**, 547–555 (2022).
33. Flemmich, L. et al. A natural riboswitch scaffold with self-methylation activity. *Nat. Commun.* **12**, 3877 (2021).
34. Jiang, H. Y. et al. The identification and characterization of a selected SAM-dependent methyltransferase ribozyme that is present in natural sequences. *Nat. Catal.* **4**, 872–881 (2021).
35. Huber, T. D., Johnson, B. R., Zhang, J. & Thorson, J. S. AdoMet analog synthesis and utilization: current state of the art. *Curr. Opin. Biotechnol.* **42**, 189–197 (2016).

36. Abdelraheem, E. et al. Methyltransferases: functions and applications. *ChemBioChem* **23**, 202200212 (2022).
37. Dalhoff, C., Lukinavicius, G., Klimasauskas, S. & Weinhold, E. Direct transfer of extended groups from synthetic cofactors by DNA methyltransferases. *Nat. Chem. Biol.* **2**, 31–32 (2006).
38. Sohtome, Y., Shimazu, T., Shinkai, Y. & Sodeoka, M. Propargylic Se-adenosyl-L-selenomethionine: a chemical tool for methylome analysis. *Acc. Chem. Res.* **54**, 3818–3827 (2021).
39. Willnow, S., Martin, M., Luscher, B. & Weinhold, E. A selenium-based click AdoMet analogue for versatile substrate labeling with wild-type protein methyltransferases. *ChemBioChem* **13**, 1167–1173 (2012).
40. Huber, T. D. et al. Functional AdoMet isosteres resistant to classical AdoMet degradation pathways. *ACS Chem. Biol.* **11**, 2484–2491 (2016).
41. Yang, K. et al. Reactivity of N3-methyl-2'-deoxyadenosine in nucleosome core particles. *Chem. Res. Toxicol.* **32**, 2118–2124 (2019).
42. Varadarajan, S. et al. DNA damage and cytotoxicity induced by minor groove binding methyl sulfonate esters. *Biochemistry* **42**, 14318–14327 (2003).
43. Yan, L. L. & Zaher, H. S. How do cells cope with RNA damage and its consequences? *J. Biol. Chem.* **294**, 15158–15171 (2019).
44. Ren, A. et al. Pistol ribozyme adopts a pseudoknot fold facilitating site-specific in-line cleavage. *Nat. Chem. Biol.* **12**, 702–708 (2016).
45. Fujii, T., Saito, T. & Nakasaka, T. Purines. XXXIV. 3-methyladenosine and 3-methyl-2'-deoxyadenosine—their synthesis, glycosidic hydrolysis, and ring fission. *Chem. Pharm. Bull.* **37**, 2601–2609 (1989).
46. Filonov, G. S., Kam, C. W., Song, W. & Jaffrey, S. R. In-gel imaging of RNA processing using broccoli reveals optimal aptamer expression strategies. *Chem. Biol.* **22**, 649–660 (2015).
47. Filonov, G. S., Moon, J. D., Svensen, N. & Jaffrey, S. R. Broccoli: rapid selection of an RNA mimic of green fluorescent protein by fluorescence-based selection and directed evolution. *J. Am. Chem. Soc.* **136**, 16299–16308 (2014).
48. Litke, J. L. & Jaffrey, S. R. Highly efficient expression of circular RNA aptamers in cells using autocatalytic transcripts. *Nat. Biotechnol.* **37**, 667–675 (2019).
49. Katrekar, D. et al. Efficient in vitro and in vivo RNA editing via recruitment of endogenous ADARs using circular guide RNAs. *Nat. Biotechnol.* **40**, 938–945 (2022).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023

Methods

RNA synthesis

RNA oligonucleotides were prepared by solid-phase synthesis using phosphoramidite chemistry with 2'-*O*-TOM-protection on controlled pore glass (CPG) solid supports⁵⁰. RNA and DNA sequences are shown in Supplementary Tables 1 and 2. Modified phosphoramidites for atonic mutagenesis, c¹A (ref. 51) and c³A (refs. 52,53), were prepared by following published procedures^{54,55}. Other modified phosphoramidites were purchased. RNA oligonucleotides were deprotected with ammonia and methylamine (AMA), followed by 1 M tetrabutylammonium fluoride in THF, desalted and purified by denaturing PAGE. The quality of RNAs (purity and identity) was analysed by anion-exchange HPLC (Dionex DNAPac PA200, 2 × 250 mm, at 60 °C; solvent A was 25 mM Tris-HCl (pH 8.0) and 6 M urea; solvent B was 25 mM Tris-HCl (pH 8.0), 6 M urea and 0.5 M NaClO₄; the gradient was linear, 0–40% solvent B, with a slope of 4% solvent B per column volume, flow rate 0.5 ml min⁻¹, UV detection at 260 nm) and HR-ESI-MS (micrOTOF-Q III, negative-mode, direct injection). Measured and calculated masses are listed in Supplementary Table 3.

Stability assay of ProSeDMA by HPLC analysis

1 mM ProSeDMA was mixed in a total volume of 100 µl of reaction buffer (50 mM HEPES, 120 mM KCl, 5 mM NaCl and 10 mM MgCl₂, pH 6.0, 7.0 or 8.0) or with cell lysate generated from HEK293T cells with RIPA buffer (150 mM NaCl, 1.0% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 7.5). The reaction mixtures were incubated at 37 °C, and 20 µl aliquots were taken from the samples to 40 µl of H₂O + 0.1% trifluoroacetic acid (TFA) solution every 1 h. The collected samples were analysed by RP-HPLC (NUCLEOSIL 100-5 C18 column; 5 µm, 125 × 4 mm). The analysis was run with a linear gradient: B conc. 5–7% (0–15 min), 7–70% (15–30 min); solvent A was H₂O + 0.1% TFA; solvent B was MeCN + 0.1% TFA; and flow rate was 0.7 ml min⁻¹ at 30 °C with UV detection at 260 nm.

In vitro selection

The initial library was prepared by in vitro transcription from double-stranded template DNA made from two synthetic DNA oligonucleotides (**D2** and **D4** with N40: A:C:G:T = 1:1:1:1) by overlap extension using Klenow fragment DNA polymerase. We used 500 pmol template DNA for in vitro transcription with T7 RNA polymerase in reaction buffer (40 mM Tris-HCl pH 8.0, 10 mM dithiothreitol (DTT), 4 mM NTP, 30 mM MgCl₂ and 2 mM spermidine). For the first selection round, the 5 nmol RNA pool (with 10% 3'-fluorescently labelled RNA, prepared by sodium periodate oxidation labelling with Lucifer yellow carbohydrazide) was annealed in selection buffer (120 mM KCl, 5 mM NaCl and 50 mM HEPES, pH 7.5; 3 min at 95 °C, then 10 min at 25 °C). Cofactor **5** or **9** was added together with MgCl₂ and the reaction filled with water to 1 ml, to give final concentrations of 5 µM RNA, 5 µM cofactor and 10 mM MgCl₂. In further selection rounds, 1 nmol RNA was used in 200 µl total volume for the selection step. After incubation at 37 °C for 1 h, an excess amount of cofactor was removed by ethanol precipitation. The reacted RNA was labelled with biotin azide via CuAAC (100 µM RNA, 500 µM biotin azide, 1 mM CuBr and 2 mM Tris((1-benzyl-4-triazolyl)methyl)amine (TBTA) in 10 µl of H₂O:DMSO:BuOH (5:3:1)). The biotinylated RNAs were captured using either neutravidin- or streptavidin-coated magnetic beads (Dynabeads, Thermo Fisher Scientific, -1 nmol RNA per mg of beads), washed according to the manufacturer's instructions and eluted with formamide and amplified by PCR with reverse transcription (RT-PCR) with Ready-to-Go RT-PCR beads (Illustra). The second PCR was done with a primer containing the T7 promoter. In vitro transcription was performed (total volume of 100 µl), followed by PAGE purification to prepare the enriched RNA library for the next selection rounds. After eight rounds of selection, the library was cloned using the TOPO-TA cloning kit, and colonies were randomly picked up for sequencing.

The catalytic activity of ribozyme candidates was checked by a streptavidin gel shift assay on native PAGE (5 pmol RNA, 1 µg of streptavidin in 1× Tris-buffered saline (TBS) buffer) after 1 h incubation with cofactors **5** or **9**, respectively, followed by CuAAC with biotin azide. The candidate **Rz3** with the highest *cis*-activity was used for further experiments.

Analysis of the propargylated RNA

For anion-exchange HPLC analysis, the substrate RNA was incubated with ProSeDMA in reaction buffer (10 µM substrate RNA, 10 µM SAMURI, 100 µM ProSeDMA and 10 mM MgCl₂) at 37 °C for 1 h and analysed by anion-exchange HPLC on a Dionex DNAPac PA200 column (8 µm, 250 × 2 mm). The analysis was run with a linear gradient of B: conc. 0–48% (0–20 min). Solvent A was 25 mM Tris-HCl (pH 8.0) and 6 M urea; solvent B was 25 mM Tris-HCl (pH 8.0), 6 M urea and 0.5 M NaClO₄. The flow rate was 0.5 ml min⁻¹ at 60 °C with UV detection at 260 nm. For the digestion assay, 10 pmol unmodified and modified RNA were treated with 0.5 U of RNase T1 in 10 µl of reaction solution (50 mM Tris-HCl, pH 7.5) for 5 min at 37 °C or in 10 µl of alkaline hydrolysis solution (25 mM NaOH) for 3 min at 95 °C. For MALDI-TOF analysis, unmodified, modified and isolated RNAs were applied on a matrix (20 mg ml⁻¹ 3-hydroxypicolinic acid and 10 mg ml⁻¹ diammonium hydrogen citrate). After drying the matrix, mass data were collected by negative-mode ionization. For LC-MS analysis, the 500 pmol unmodified and modified RNA were digested by 6.0 U of bacterial alkaline phosphatase and 1.0 U of SVPD in reaction buffer (40 mM Tris-HCl, 20 mM MgCl₂, pH 7.5). After extracting the digested nucleoside mixture with 100 µl of chloroform, the aqueous layer was concentrated by lyophilization, and the residue was dissolved in 70 µl of 5 mM NH₄OAc and analysed by LC-MS, using a Synergi Fusion RP column (Phenomenex, 4 µm, 250 × 2 mm). The analysis was run with a gradient of 0–5% (0–15 min) and 5–72.5% (15–45 min) of solvent B. Solvent A was 10 mM NH₄OAc (pH 5.3), solvent B was MeCN and the flow rate was 0.2 ml min⁻¹ at 25 °C with UV detection at 260 nm and online MS in a microTOF-Q III system in positive-ion mode.

Kinetic assays of SAMURI-catalysed *trans*-alkylation reactions

We mixed 10 pmol of Cy5-labelled RNA and 100 pmol of SAMURI in reaction buffer (50 mM HEPES, 120 mM KCl and 5 mM NaCl). After an annealing step (3 min at 95 °C and 10 min at 25 °C), 10 mM MgCl₂ and 100 pmol of cofactor were added and the water was filled up until the total volume was 10 µl. The mixture was incubated at 37 °C and 1 µl aliquots were taken at desired time points and quenched by adding 4 µl of stop solution (80% formamide, 89 mM Tris-HCl, 89 mM boric acid and 50 mM EDTA). Each time-point sample was analysed by denaturing PAGE (20% polyacrylamide), and the band intensities were quantified by fluorescence imaging using a 695/55-nm emission filter. The yield versus time data were fitted to $Y = Y_{\max}(1 - \exp(-k_{\text{obs}}t))$ using Origin (2019). All kinetic assays were carried out as three independent replicates. For determination of apparent K_m values, k_{obs} was determined with different concentrations of ProSeDMA and the k_{obs} versus concentration data were fitted using the Michaelis–Menten equation.

Construction of *cis*-active SAMURI containing plasmids

The insert of *cis*-active SAMURI was prepared by overlap extension of amplicon from previously reported plasmid³¹ and synthetic DNA oligonucleotides (details are provided in Supplementary Fig. 1). The insert DNA was cloned between the NotI and SacII sites of pAV-U6 + 27-Tornado-Broccoli (Addgene plasmid no. 25709). The sequence of the insert and successful ligation into the plasmid were confirmed by Sanger sequencing.

Cell culture and transfection

1 × 10⁵ HEK293T cells (ATCC) were cultured in 1 ml of 1× Dulbecco's modified Eagle medium (Life Technologies) with 10% fetal bovine

serum, 100 U ml⁻¹ penicillin and 100 µg ml⁻¹ streptomycin in a 12-well culture plate. Cells were plated for transfection using FuGENE HD (Promega), according to the manufacturer's instructions, with 2 µg cSAMURI plasmid in OptiMEM I reduced serum medium (Gibco). RNA expression was checked by fluorescent microscopy (ZOE, Bio-Rad) with DFHBI-1T. After 48 h of incubation, total RNA was collected from the cultured cells by mixing with Trizol LS reagent (Invitrogen).

Cell viability assay

HEK293T cells were cultured in 1 ml of 1× Dulbecco's modified Eagle medium with 10% fetal bovine serum, 100 U ml⁻¹ penicillin and 100 µg ml⁻¹ streptomycin in a 24-well culture plate. After 24 h, the medium was replaced by 0.5 ml OptiMEM containing 0.1–3 mM ProSeDMA and 50 mM HEPES (pH 7.5) and the cells were incubated for 6 h. The cells were then extensively washed with PBS and mixed with 0.4% trypan blue solution (Thermo Fisher Scientific) in a 1:1 ratio. After 5 min of incubation at room temperature, total and stained cells were counted and cell viability was calculated as (1 – (number of stained cells/number of total cells)) × 100 (%).

Analysis of cellular uptake of ProSeDMA by LC-MS

HEK293T cells were seeded in a 12-well culture plate and grown for 24 h. The medium was replaced by 1 ml of OptiMEM containing 0, 0.1, 0.5, 1 or 3 mM ProSeDMA, 5 µg ml⁻¹ actD and 50 mM HEPES (pH 7.5) and incubated for 1 h. The incubated cells were washed three times with 1× PBS and suspended in 200 µl of 50% methanol + 0.1% formic acid. The suspended cells were completely disrupted by sonication. The resulting cell lysate was extracted with 200 µl of chloroform and the water phase was evaporated. After evaporation, the residue was dissolved in 100 µl of H₂O containing 0.1% formic acid. After filtration, 50 µl of the sample was injected into an LC/MS system using an RP-column (NUCLEOSIL 100-5 C18 column, 5 µm, 125 × 4 mm). The analysis was run with a linear gradient of B: conc. 3% (0–15 min), 3–23% (15–30 min); solvent A was H₂O + 0.1% formic acid, solvent B was MeCN + 0.1% formic acid and the flow rate was 0.2 ml min⁻¹ at 25 °C with UV detection at 260 nm. The micrOTOF-Q III with an ESI ion source was operated in positive-ion mode (MS range, 50–2,500), with a capillary voltage of 4.5 kV, end plate offset of 500 V, nitrogen nebulizer pressure of 1.4 bar, dry gas flow of 9 l min⁻¹ and dry temperature of 200 °C. Data were analysed with Data Analysis software DA 4.2 (Bruker Daltonics). For the calibration curve, multiple concentrations of ProSeDMA (0.05, 0.25, 0.5, 2.5 and 5 nmol) were spiked into cell lysate generated from cells that were not treated with ProSeDMA, and the peak areas of the ProSeDMA extracted ion chromatograms were plotted against the ProSeDMA amount injected. The slope was determined and used for calculation of the concentration of ProSeDMA in the lysate of cells that were fed with ProSeDMA in the medium.

Intracellular activity assay of *cis*-active ribozyme

After transfection, cells were cultured for 48 h and then the medium was replaced by 1 ml of OptiMEM containing 0.1–3 mM ProSeDMA, 5 µg ml⁻¹ actD (RNA transcription inhibitor) and 50 mM HEPES (pH 7.5). After 6 h of incubation, the cells were extensively washed and total RNAs were collected by Trizol LS reagent. The collected RNA was labelled by the CuAAC reaction (200 ng RNA, 500 µM CuBr, 1 mM TBTA and 1 mM Cy5 azide were incubated in H₂O/DMSO/^tBuOH = 5/3/1 solution at 37 °C for 1 h). Labelled RNAs were analysed by 5% denaturing PAGE, and the gel was imaged in the Cy5 channel before staining with DFHBI-1T and SYBR Gold. The band intensities were quantified and the intracellular activity was calculated from the Cy5/DFHBI-1T ratio, relative to the *in vitro* labelling efficiency of total RNA extracted from cells that were not treated with ProSeDMA. This control was prepared by labelling in the test tube (200 ng total RNA, 50 µM ProSeDMA and 10 mM MgCl₂, pH 7.5 at 37 °C for 1 h).

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this Article.

Data availability

The data generated and analysed during this study are included in this published Article, in the Supplementary Information and in the source data files. Source data are provided with this paper.

References

- Pitsch, S. et al. Reliable chemical synthesis of oligo-ribonucleotides (RNA) with 2'-O-[(trisisopropylsilyloxy)methyl(2'-O-tom)-protected phosphoramidites. *Helv. Chim. Acta* **84**, 3773–3795 (2001).
- Cristalli, G. et al. Improved synthesis and antitumor activity of 1-deazaadenosine. *J. Med. Chem.* **30**, 1686–1688 (1987).
- Mairhofer, E., Fuchs, E. & Micura, R. Facile synthesis of a 3-deazaadenosine phosphoramidite for RNA solid-phase synthesis. *Beilstein J. Org. Chem.* **12**, 2556–2562 (2016).
- Erlacher, M. D. et al. Efficient ribosomal peptidyl transfer critically relies on the presence of the ribose 2'-OH at A2451 of 23S rRNA. *J. Am. Chem. Soc.* **128**, 4453–4459 (2006).
- Spitale, R. C. et al. Single-atom imino substitutions at A9 and A10 reveal distinct effects on the fold and function of the hairpin ribozyme catalytic core. *Biochemistry* **48**, 7777–7779 (2009).
- Bereiter, R. et al. Impact of 3-deazapurine nucleobases on RNA properties. *Nucleic Acids Res.* **49**, 4281–4293 (2021).

Acknowledgements

This work was supported by the European Research Council (ERC; grant no. 682586), the Deutsche Forschungsgemeinschaft (DFG; grant no. 463143961) and the University of Würzburg. We thank N. Knickmeier for the synthesis of nucleoside precursors, L. Pfeuffer and B. Plaschke for cell culture assistance, J. Adelman for help with LC-MS analyses, and C.P.M. Scheitl and T. Kerrinnes for discussions.

Author contributions

T.O. and C.H. conceived the study and designed the experiments. T.O. conducted the experiments and collected and analysed the data. A.K.L. and F.S. synthesized the reagents. J.V. supervised the cell culture experiments. T.O. and C.H. prepared the figures and wrote the manuscript. All authors discussed the results.

Competing interests

The authors declare no competing interests.

Additional information


Extended data is available for this paper at <https://doi.org/10.1038/s41557-023-01320-z>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41557-023-01320-z>.

Correspondence and requests for materials should be addressed to Claudia Höbartner.

Peer review information *Nature Chemistry* thanks Seung Soo Oh and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.


Reprints and permissions information is available at www.nature.com/reprints.



Extended Data Fig. 1 | See next page for caption.

Extended Data Fig. 1 | Enzymatic recognition of SAM analogues by MTase (M.EcoRI). **a.** Structures of cofactors used. **b.** Plasmid (pET-14b) was subjected to enzymatic modification with M.EcoRI and the respective cofactor, and the modification efficiency was analyzed by restriction enzyme R.EcoRI. **c.** Plasmid (pET-14b) was first linearized by digestion with restriction enzyme PvuII, and then treated as in **b.** Transalkylation conditions: 150 ng Plasmid / linear DNA, 100 μ M


SAM analogue, 50 mM Tris-HCl, 50 mM NaCl, 10 mM EDTA (pH = 8.0), 40 U M.EcoRI MTase 37 °C for 1 h. Then the MTase was inactivated by heating to 65 °C for 20 min. Restriction enzyme condition: 20 U R.EcoRI, 37 °C for 1 h. Analysis condition: 0.8% agarose gel (75 V, 45 min), staining: SYBR green. Representative images of two independent experiments with similar results are shown.



Extended Data Fig. 2 | In vitro selection of trans-propargylation ribozymes.


In vitro selection was proceeded by incubation, CuAAC reaction, separation, amplification and transcription steps. The RNA library contains an unpaired adenosine (red, A) and is connected to the 40 random nucleotides via the single-stranded loop. Incubation was done in 5 μ M RNA, 5 μ M cofactor **5** or **9**, 50 mM HEPES, pH 7.5, 120 mM KCl, 5 mM NaCl and 10 mM MgCl₂, at 37 °C for 1 h. Then, propargylated RNA was modified with biotin in 100 μ M RNA, 500 μ M biotin azide, 1 mM CuBr and 2 mM TBTA. For capture, beads were blocked with *E. coli* tRNA; streptavidin and neutravidin beads were switched every two rounds.

Denaturing wash buffer was 8 M urea, 10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 0.01% Tween-20. Elution used 95% formamide, 1 mM EDTA, at 95 °C for 5 min. For RT-PCR, one-pot RT-PCR reaction was used with the following conditions: 42 °C, 30 min, 10 cycles of PCR with 1 μ M primer **D5** and 0.5 μ M primer **D3**. For the following PCR, we used: 30 cycles, 10% (v/v) RT-PCR product as template, 1 μ M **D4** and 0.5 μ M **D5**, 10% (v/v) DMSO, and an annealing temperature of 63 °C. For in vitro transcription, T7 RNA polymerase was used with dsDNA template obtained from a 200 μ L PCR reaction, in 100 μ L transcription reaction volume with 4 mM each NTP, 37 °C for 15 h, followed by PAGE purification.



Extended Data Fig. 3 | Identification of candidates of alkyltransferase ribozyme from in vitro selection libraries. Four sequences were identified from each library (OH series used cofactor 9; NH₂ series used cofactor 5 during


selection). Trans alkylation activity was evaluated by streptavidin gel shift assay on native PAGE (the qualitative screening assay was performed once). Condition: 5 pmol RNA, 1 μg of streptavidin in 1x TBS buffer.




Extended Data Fig. 4 | See next page for caption.

Extended Data Fig. 4 | Sequence and predicted secondary structure of Rz3 ribozyme and its trans-active variants. **a.** Minimization and mutation analysis. Conditions for trans activity assay: 1 μ M 3'-labelled substrate RNA, 1 μ M Rz3 or indicated mutant, 10 μ M ProSeDMA and 10 mM MgCl₂ were incubated at 37 °C for 1 h. **b.** Primer extension assay was performed after incubation of cis-Rz3' transcript with ProSeDMA or MeSeDMA. Condition: 10 pmol modified cis ribozyme, 10 pmol FAM labelled DNA primer, 1x first strand buffer (50 mM Tris-HCl pH8.3, 75 mM KCl and 3 mM MgCl₂), 5 mM DTT, 0.5 mM of each dNTP and SuperScript III RT (ThermoFisherScientific) were incubated at 55 °C for 30 min. **c.** Transplanting the catalytic core to target an alternative adenosine (A9 instead

of A5). Conditions as in (a) for 1 h, 3 h, or overnight (ON). NT, no treatment. Products (P) were isolated and subjected to alkaline hydrolysis. The shifted band in comparison to the alkaline hydrolysis pattern of the unmodified RNA (S) identified the modification site. **d.** SAMURI activity and sequence specificity with different base-pairs flanking the modification site. The mutated ribozymes and 19-nt long substrate RNAs were prepared by *in vitro* transcription. The substrate RNAs were labelled with fluorescein at the 3'-end after oxidation with periodate. SAMURI reaction conditions as in (a) with time points up to 1 h as indicated. Representative images are shown of two (a, b, c) or three (d) independent experiments with similar results.




Extended Data Fig. 5 | Mass spectrometric analysis of alkylated RNA products including atomic mutagenesis. ESI-MS of PAGE-purified 17-nt RNAs (5'-ACAUCUGAGCCUCAA-Cy5); deconvoluted mass spectra are shown; Chemical formula and calculated masses are given in the Supporting Information (Supplementary Table 3).




Extended Data Fig. 6 | Scope of SAMURI trans activity. Gel images for kinetics graphs shown in Fig. 3f (ProSeDMA and ProSeAM gels are same as in Fig. 3f, here reproduced for comparison). Conditions: 10 pmol Cy5 labelled substrate RNA and 100 pmol SAMURI in reaction buffer (50 mM HEPES, 120 mM KCl and 5 mM NaCl); after annealing (3 min at 95 °C, 10 min at 25 °C), 10 mM MgCl₂ and 100

pmol respective cofactor (or 30 nmol SAM) were added (total reaction volume 10 μL). Incubation at 37 °C, 1 μL aliquots mixed with 4 μL of stop solution; k_{obs} determined from pseudo-first order curve fit; Representative gel images of three independent replicates for all cofactors, except for MeSeDMA and SAM two replicates.



Extended Data Fig. 7 | LC/MS analysis of digested RNA products containing methyl (a) and allyl (b) modification. a,b, After incubation with SAMURI and MeSeDMA or AlISeDMA, respectively, the RNAs were isolated by PAGE and then digested by bacterial alkaline phosphatase and snake venom phosphodiesterase (in 40 mM Tris-HCl, 20 mM MgCl₂, pH 7.5). After extraction with chloroform, the aqueous layer was concentrated, and the residue was dissolved in 70 μ L

5 mM NH₄OAc and analyzed by LC-MS, using a Synergi Fusion RP HPLC column (Phenomenex, 4 μ m, 250 \times 2 mm). The analysis was run with a gradient of B from 0% - 5% (0 min to 15 min) and 5% - 72.5% (15 min to 45 min); solvent A was 10 mM NH₄OAc (pH 5.3); solvent B was MeCN; flow rate was 0.2 mL/min at 25 $^{\circ}$ C with UV detection at 260 nm and ESI mass spectrometry in positive-ion mode.

**Extended Data Fig. 8 | LC/MS analysis of ProSeDMA in HEK293T cell lysate.**

a. Schematic illustration for generation of a calibration curve with known concentrations of ProSeDMA spiked into HEK293T cell lysate. **b.** Extracted ion chromatogram (EIC) for ProSeDMA and MS spectrum at 17 min retention time in cell lysate. The fragmentation pattern was as detected by HR-ESI analysis of purified cofactor (shown in supporting information). **c.** Calibration curve of peak area versus injected amount of ProSeDMA; mean \pm SD of three independent

experiments. **d.** Schematic illustration of LC/MS analysis of ProSeDMA in the lysate of cells which were treated with various concentrations of ProSeDMA (0, 0.1, 0.5, 1, 3 mM in the medium). **e.** Detected ProSeDMA EIC chromatogram peak from cell samples. **f.** Detected peak area from the samples in **e** plotted on the calibration curve from **c**. **g.** ProSeDMA concentration in the cell lysate, calculated in nmol/ 10^6 cells. Individual data points and the mean \pm SD of three independent experiments are shown.

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- | n/a | Confirmed |
|-------------------------------------|--|
| <input type="checkbox"/> | <input checked="" type="checkbox"/> The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> The statistical test(s) used AND whether they are one- or two-sided
<i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i> |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> A description of all covariates tested |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
<i>Give P values as exact values whenever suitable.</i> |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated |

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection gel images with fluorescently labeled RNA: BioRad Chemidoc; BioRad fluorescent cell imager; Anion exchange HPLC: Dionex DNAPAc column on ÄKTA micro; RP-HPLC: Nucleosil column on Jasco HPLC; UV detection at 260 nm; LC-MS: ThermoUltimate3000 HPLC with Synergi RP C18 column. HR-ESI-MS: Bruker MicroToF-QIII.

Data analysis Origin (2019), Compass Data Analysis software 4.2 (Bruker Daltonics)

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The data generated and analysed during this study are included in this published article, in the Supplementary Information and in the Source Data files.

Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

Reporting on sex and gender	<input type="text" value="not applicable"/>
Population characteristics	<input type="text" value="not applicable"/>
Recruitment	<input type="text" value="not applicable"/>
Ethics oversight	<input type="text" value="not applicable"/>

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	<input type="text" value="Samples sizes for experiments with transfected HEK293T cells: 100,000 cells were seeded in 12-well culture plate and grown for 24 h prior to the respective experiments, as described in material and methods. For cell viability assays, 24-well culture plates were used."/>
Data exclusions	<input type="text" value="No data was excluded from the analyses."/>
Replication	<input type="text" value="For all biochemical assays described in the manuscript, the experiments were performed in two or three independent replicates (described in material and methods), following the common standards in the field of ribozyme characterization. All attempts of replication were successful."/>
Randomization	<input type="text" value="Randomization was not required, since no organisms/animal or human subjects were used in this study, and because ribozyme characterization was done by measuring physical values, which are not influenced by the observer."/>
Blinding	<input type="text" value="blinding was not relevant to the study, because there was no manual scoring involved."/>

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involvement in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

Methods

n/a	Involvement in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

Cell line source(s)	<input type="text" value="Human embryonic kidney (HEK) 293T cell was purchased from the American Type Culture Collection (ATCC)."/>
Authentication	<input type="text" value="The cell lines was authenticated by vendor by STR profiling."/>

Mycoplasma contamination

The cell was tested negative for mycoplasma contamination before passaging.

Commonly misidentified lines
(See [ICLAC](#) register)

No commonly misidentified cell lines were used.